Lipids & metabolic liver disease
Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin
Authors' conclusion
In this group of patients with MASLD, sASGR1 levels are higher and are associated with the occurrence of MASLD, suggesting that sASGR1 may be an independent risk factor for MASLD.
Study context
- Population
- Patients with MASLD and general-population controls without MASLD
- Participants
- 148 vs 98
- Comparison
- MASLD vs controls without MASLD
- MASLDn = 148
- Controln = 98reference
- Outcome
- Serum sASGR1 levels
Main finding
As reported in the abstract
- Higher serum soluble ASGR1 (sASGR1) in MASLD vs control
- MASLD vs Control: P < 0.05
Observational data: associations, not effects.
Further findings
sASGR1 as independent risk factor for MASLD (multiple regression, adjusted)
- OR 2.644, 95% CI 1.138 to 6.143; p<0.05
- Adjusted for potential confounding factors
AUC of serum sASGR1 for predicting MASLD
- sASGR1 alone, AUC
- 0.761 (95% CI 0.698 to 0.824)
- sASGR1 combined with AST and ALT, AUC
- 0.863 (95% CI 0.813 to 0.913)
Spearman correlations of serum sASGR1
- Positive correlation with TG, total cholesterol, LDL-C, FPG, fasting insulin, HbA1c, HOMA-IR, TNF-α, ALT, AST, GGT, procollagen type III, hyaluronic acid and BMI (p<0.05)
- Negative correlation with HDL-C (p<0.05)
Original publication
Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin. BMJ Open Diabetes Res Care. Published 27 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →